Sintilimab Plus Chemotherapy for Unresectable Gastric or Gastroesophageal Junction Cancer

Jianming Xu(Chinese PLA General Hospital), Hongyu Zhang(Jiangnan University), Suxia Luo(Henan Cancer Hospital), Liangming Zhang(Sun Yat-sen University), Shirong Cai(Sun Yat-sen University), Ziran Li, Shundong Cang(Henan University), Hongming Pan(Sir Run Run Shaw Hospital), Jieer Ying(Chinese Academy of Medical Sciences & Peking Union Medical College), Yongqian Shu(Jiangsu Cancer Hospital), Yingmei Guo, Zuoxing Niu(Shandong Tumor Hospital), Yanru Qin(First Affiliated Hospital of Zhengzhou University), Min Tao(Army Medical University), Haiping Jiang(California Institute for Regenerative Medicine), Zhilong Yan(Ningbo University), Junhe Li(First Affiliated Hospital of Xiamen University), Aimin Zang, Yong Tang(Xinjiang Medical University), Yuxian Bai(Harbin Medical University), Qi Wang(Soochow University), Tao Zhang, Ying Liu(Peking University), Minghui Zhang(Chifeng Municipal Hospital), Jiayi Li(First Affiliated Hospital of Xiamen University), Junhui Zhao(Qinghai University Affiliated Hospital), Lei Han(Affiliated Hospital of Jining Medical University), Hongmei Sun, Hui Zhou, Chunhong Hu(Central South University), Jianwei Yang(Fujian Provincial Cancer Hospital), Hui Yang, Shubin Wang, Ling Yang(Hangzhou Cancer Hospital), Kangsheng Gu(Anhui Medical University), Jun Liang(Peking University), Jingdong Zhang(Liaoning Cancer Hospital & Institute), Bo Peng(University of Groningen), Weijian Guo, Lei Yang(Nantong Tumor Hospital), Yifu He(Anhui Provincial Hospital), Da Jiang(The Third Affiliated Hospital of Zhejiang Chinese Medical University), Rui Mao, Qunyi Guo(Wenzhou Medical University), Yan Wang(Weifang Medical University), Yueyin Pan(University of Science and Technology of China), Xinjun Liang(Hubei Cancer Hospital), Yong Mao(Jiangnan University)
JAMA
December 5, 2023
10.1001/jama.2023.19918
Cited by 384

Related Papers

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial
|The Lancet|2012|1.4k
Hepatogastroenterology
|Hepatogastroenterology|2012|1.3k
Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial
|The Lancet|2023|1.1k
Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study
|Journal of Clinical Oncology|2013|775